



medibio

Investor Update

February 2019

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY

Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Medibio Limited (ASX:MEB) (OTCQB: MDBIF). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

The logo for medibio features the word "medibio" in a lowercase, sans-serif font. The letters "med" are in a dark blue color, "i" is in a light blue, "b" is in a purple, and "io" are in an orange. The logo is centered within a large, faint, circular pattern of white dots that radiates outwards from the center of the page.

medibio

The mental health technology company leveraging objective digital biomarkers for products and services that assist in screening, diagnosing, monitoring, and managing of depression and other mental health conditions.

Corporate Structure

CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

Market Cap	AU\$4.26M
Share price <i>as of 12 February 2019</i>	AU\$0.021
Shares on Issue	203M
Cash¹	AU\$2.2M

1. Cash balance as of 31 December 2018.

2. Percentages based on available information, including share registry, options listing, ASX filings, and other reported data

3. Includes shares on issue and vested board & management options

Significant Institutional Investors

 **9.1%**

Fidelity

 **7.0%**

Regal Funds Management

Shareholder Mix^{2, 3}

Private Holders **57.2%**

Institutional Holders **40.1%**

Board and Management **2.7%**

NEW FOCUS STRATEGY

Medibio is pleased to have implemented its new focus strategy

- ✓ Restructured Board and Key Management
- ✓ New Cost Controls to Reduce Cash Burn
- ✓ Strengthened Regulatory Path
- ✓ Prioritised Business Segments
- ✓ Enhanced Communication with Stakeholders

RESTRUCTURED BOARD AND KEY MANAGEMENT

4 February 2019

Peggy Morgan appointed as Corporate Controller

1 January 2018

Brian Mower, as part of cost savings, ceased as CFO

31 December 2018

Claude Solitario appointed as a Non-Executive Board member

31 December 2018

Peter Carlisle appointed Interim Chairman of Board

31 December 2018

Christopher Indermaur ceased as Non-Executive Chairman

5 November 2018

David B. Kaysen, Seasoned MedTech Executive, appointed CEO and Managing Director



Board of Directors



PETER CARLISLE
Interim Chairman
Managing Director, Olympics &
Action Sports, Octagon Worldwide



DR FRANKLYN G PRENDERGAST
PhD MD, Non Executive Board Member
Former member board of Trustee and Board of
Governors Mayo Clinic and board member Eli Lilly



PATRICK KENNEDY
Non Executive Director
Former US Congressman
Founder, Kennedy Forum



ANDREW MAXWELL
Non Executive Director
MBA, MAcc, ACPA



MICHAEL PHELPS
Non Executive Director
Mental Health Advocate



CLAUDE SOLITARIO
Non Executive Director



DAVID KAYSER
CEO & Managing Director



MELANIE LEYDIN
Company Secretary
B. Bus. (UTS), Grad. Dip. DP (UTS), CA, AGIA

Executive Team



DAVID KAYSEN
Chief Executive Officer



PEGGY MORGAN
Corporate Controller



ARCHIE DEFILLO
Chief Medical Officer



JEREMY SCHROETTER
Chief Technology Officer



LINDSEY HAGAN
Vice President Integrated Health



JENNIFER SOLITARIO
Senior Vice President Corporate Health



PATRICK MIDDEN
Chief Privacy Officer

COST CONTROLS TO REDUCE CASH BURN


Focus on reducing cash burn over past 45 days

- Significant reduction in force, U.S. office
- Cash compensation eliminated for NED's, effective 1 January 2019
- All line item spending scrutinised & reduced
- Reduction in spending in Australian office


Goal with Entitlement Offer is expected to provide 12+ months of cash



QUARTERLY CASH BURN



BUSINESS Objectives – Pipeline to deliver against new strategy focus



PRODUCT OVERVIEW – Two Core Offerings

FDA De Novo
FDA 510(k)



- ▶ Mental Health Regulated Product – FDA Clearance Process in the U.S.
- ▶ Expect 510(k) decision within first 4 - 5 months of 2019
 - Product focused on providing clinicians new data points
 - Gather data on Heart Rate Variability (HRV)
 - Gather additional data from in-patient sleep studies
- ▶ Improve Clinician assessment of patient's mental health
- ▶ Continue to respond to FDA De Novo Application
 - 29 April 2019 MEB to respond to FDA questions
 - Time consuming process
 - Outcome is yet to be determined

PRODUCT OVERVIEW – Two Core Offerings

Australia

ilumen™ in Corporate Health Market




- ▶ Start small with Pilots
 - Marketed to large corporations with goal to scale up partnerships
- ▶ App based system provides feedback to individual
 - Provides de-identified feedback to Corporate partner
- ▶ One pilot completed with very high participation
- ▶ AIAA pilot to start by March 1
- ▶ Receiving unsolicited inquiries from large corporations
- ▶ Being selective due to constraints with funding and people



Looking to Expand...

- Focus on Better Use of Biometrics
- Continue to Improve Biometric Algorithm (based on wearable data collected)



RECENT CAPITAL RAISING

- ▶ Completed Convertible Note issue in January 2019, raising approximately \$2.75 million over two tranches
- ▶ Currently undertaking a Non-Renounceable Entitlement Offer to existing shareholders:
 - Offer to purchase 1 new MEB share for each MEB share held at the record date
 - \$0.02 per share (same as the Convertible Note offer)
 - Any shortfall will be marketed to new investors
- ▶ The combined capital raisings, with cost savings in place, is expected to provide 12+ months of cash
- ▶ This Entitlement Offer is important – **your support is appreciated**

medibio

THANK YOU

8696 Eagle Creek Circle
Savage, MN 55378 USA

[medibio.com.au](https://www.medibio.com.au)

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY